Recruiting Alzheimers Disease Studies in Walnut Creek
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the st...
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease....
A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in participants with mild to moderate Alzheimer's d...
Senicapoc in Alzheimer's Disease
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients wit...
About Alzheimers Disease Clinical Trials in Walnut Creek
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Walnut Creek, CALIFORNIA. These studies are seeking a combined 1,027 participants. Research is being sponsored by Karuna Therapeutics, Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Walnut Creek — FAQ
Are there alzheimers disease clinical trials in Walnut Creek?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Walnut Creek, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Walnut Creek?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Walnut Creek research site will contact you about next steps.
Are clinical trials in Walnut Creek free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Walnut Creek studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Walnut Creek are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov